恩度联合化疗治疗难治性实体恶性肿瘤不良反应的观察与护理  

Nursing and Observation of the Side Effect of Recombinant Human Endostar Combined with Chemotherapy for Refractory Solid Tumors

作　　者：蔡丽容[1] 刘东霞[1] 陈冰[1] CAI Li-rong, LIU Dong-xia, CHEN Bing （Affiliated Tumour Hospital,Guangzhou Zhongshan University,Guangzhou 510060,China）

机构地区：[1]广州市中山大学附属肿瘤医院,广东广州510060

出　　处：《医学信息》2011年第14期4547-4548,共2页Journal of Medical Information

摘　　要：目的探讨重组人血管内皮抑制素（商品名恩度）联合化疗治疗难治性恶性肿瘤患者的疗效及不良反应的观察与护理。方法观察20例转移性实体肿瘤患者接受重组人血管内皮抑制素联合化疗不良反应的发生情况，并给予针对性的护理。结果在17例可评价病例中．PR4例（23．5％）、SD8例（47．1％）、PD5例（29．5％），有效率为23．5％，疾病控制率为70．6％；恩度联合化疗的常见不良反应包括骨髓抑制10例（50％），心脏毒性6例（30％），出血3例（150A-），胃肠道反应7例（35％）；针对性的护理有助于及时发现和（或）减轻患者的不良反应。结论恩度联合化疗治疗难治性实体肿瘤是安全的，并且显示抗瘤活性，有一定协同作用；用药期间较为常见的不良反应依次为：骨髓抑制、胃肠道反应、心脏毒性和出血倾向；为了及时发现和（或）减轻患者治疗中所产生的各种不良反应、针对性的护理干预是必要的，也是行之有效的。Objective To investigate the nursing observation of the efficacy and side effect of Recombinant human endostatin （Endostar） combined with chemotherapy for refractory solid tumors. Method： To observe the occurrence of side effect among 20 patients with refractory solid tumors who accepted endostar combined with chemotherapy and corresponding nursing if necessary. Results Among the 17 evaluatable cases there were four partial response（23.5%）, eight stable （47.1%）and five progression（29.5%）.The response rate is 23.5% and disease control rate is 70.6%. Regarding to the common side effect of Endostar, myelosuppression occurred with 50%（10/20）, cardiac toxicity with 30%（6/20）, haemorrhage with 15%（3/20） and reaction of the gastrointestinal tract with 35% （7/20）. Conclusios It is safe and effective for the combination of Endostar with chemotherapy for refractory solid tumors. Also the anticarcinogenic activety was present there is synergistic effect in part. The common side effects of Endostar were myelosuppression, reaction of the gastrointestinal tract, cardiac toxicity and haemorrhage in order. It is necessary and effective to find and/or reduce all side effects during the process of treatment and to give corresponding nursing intervention in time.

关 键 词：血管内皮抑制素 难治性实体肿瘤 化疗 护理 

分 类 号：R978[医药卫生—药品;医药卫生—药学]